Compare TBBK & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | ANIP |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2005 | 1999 |
| Metric | TBBK | ANIP |
|---|---|---|
| Price | $44.47 | $68.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $63.33 | ★ $103.38 |
| AVG Volume (30 Days) | ★ 528.5K | 347.3K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.69 | ★ 419.23 |
| EPS | ★ 4.39 | 3.86 |
| Revenue | $141,147,000.00 | ★ $206,547,000.00 |
| Revenue This Year | N/A | $24.30 |
| Revenue Next Year | N/A | $10.96 |
| P/E Ratio | ★ $10.07 | $17.92 |
| Revenue Growth | ★ 20.85 | 2.47 |
| 52 Week Low | $43.54 | $67.38 |
| 52 Week High | $73.02 | $87.76 |
| Indicator | TBBK | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 30.70 | 41.46 |
| Support Level | N/A | N/A |
| Resistance Level | $51.18 | $74.86 |
| Average True Range (ATR) | 1.60 | 2.49 |
| MACD | -0.32 | -0.08 |
| Stochastic Oscillator | 11.76 | 14.68 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.